Wellthy Therapeutics’ Data Shows Significant Blood Pressure Reduction

Wellthy Therapeutics presented their real-world evidence on how participants with hypertension, along with a co-morbidity, established a significant reduction in blood pressure levels with the help of a digital therapeutic intervention. A retrospective analysis of comorbidity levels like blood sugar also showed positive results. The abstract was published at the World Cardiology Congress organised by the American College of Cardiology.

In this study, 66 participants who were diagnosed with hypertension and type 2 diabetes mellitus, and spent at least 12 weeks on the Wellthy Care™ Digital Therapeutics (DTx) platform were observed.   

Participants engaged with the digital therapeutics platform that provided condition-specific patient education, real time and asynchronous monitoring and  guidance to improve their self-management skills and actions while providing decision-making and relevant support on self-reported data like blood pressure, blood sugar, meals, activity and other daily life parameters that positively impact the condition.

Before intervention, the baseline mean systolic blood pressure (SBP) was 135.1 mmHg while the mean diastolic blood pressure (DBP) was 86.7 mmHg. After intervention, there was a significant mean reduction in SBP by 7.4 mmHg and DBP of 3.7mmHg. Among patients with stage 2 hypertension, 47% achieved an even higher mean reduction of 12.6 mmHg in SBP and of 8.7 mmHg in DBP.

Further analysis of study participants who also had diabetes as a co-morbidity revealed a reduction in average blood sugar levels by 40.2 mg/dl. Significant reductions were noticed for both fasting blood sugar levels and postprandial blood sugar levels.

“Self Management of patients and relevant patient education is critical to hypertension control and better cardiovascular health. Maintaining a healthy and relevant diet, exercise, optimal weight, accurate self-monitoring with proper instrument, and medication adherence all play a significant role and are part of the first line of recommendation. With their busy practice, doctors find it hard to extend the necessary time to achieve the required non-pharmacotherapy goals. I’m pleased to see the results in this study, which shows real-world evidence of Wellthy Therapeutics’ digital therapeutic for hypertension and multi-morbidity management in bridging this gap for patients and doctors,” said Dr. Snehal Sanghavi, Consulting Internist & Clinical Cardiologist, and one of the authors of the abstract.

“Almost 30% of people in India have hypertension1 and up to 10% have more than one chronic lifestyle illness2. Managing multimorbidities can be overwhelming for anyone, and if left unchallenged, can seriously increase the risk of complications and impact quality of life. We are excited to show the results of our ongoing research as we continue to help participants manage all of their health, not just one condition,” said Abhishek Shah, CEO, Wellthy Therapeutics.